Cabozantinib and Weakness - a phase IV clinical study of FDA data

Summary:

Weakness is reported as a side effect among people who take Cabozantinib (cabozantinib), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Omeprazole, and have Renal cell carcinoma.

The phase IV clinical study analyzes which people have Weakness when taking Cabozantinib. It is created by eHealthMe based on reports of 1,313 people who have side effects when taking Cabozantinib from the FDA, and is updated regularly.

What is Cabozantinib?

Cabozantinib has active ingredients of cabozantinib. eHealthMe is studying from 1,313 Cabozantinib users. Check the latest studies of Cabozantinib.

What is Weakness?

Weakness is found to be associated with 3,638 drugs and 6,618 conditions by eHealthMe. Check the latest studies of Weakness.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 03, 2026

1,313 people reported to have side effects when taking Cabozantinib.
Among them, 65 people (4.95%) have Weakness.

Among these 65 people:

How long have people been on Cabozantinib when they have Weakness? *

What is the gender of people who have Weakness when taking Cabozantinib? *

female: 39.39 %
male: 60.61 %

What is the age of people who have Weakness when taking Cabozantinib? *

What are other drugs people take besides Cabozantinib? *

What are other side effects people have besides Weakness? *

Diarrhea: 20 people, 30.77%
Nausea (feeling of having an urge to vomit): 17 people, 26.15%
Palmar-Plantar Erythrodysaesthesia Syndrome (hand-foot syndrome): 16 people, 24.62%
Fatigue (feeling of tiredness): 10 people, 15.38%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 8 people, 12.31%
Weight Decreased: 8 people, 12.31%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 7 people, 10.77%
Mucosal Inflammation (infection of mucous membrane): 7 people, 10.77%
Alanine Aminotransferase Increased: 7 people, 10.77%
Joint Pain: 7 people, 10.77%

What are the existing conditions these people have? *

Renal Cell Carcinoma (a kidney cancer): 36 people, 55.38%
High Blood Pressure: 12 people, 18.46%
Hepatocellular Carcinoma (liver cancer): 9 people, 13.85%
Pain: 8 people, 12.31%
Glaucoma (increased fluid pressure in the eye with vision loss): 5 people, 7.69%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 5 people, 7.69%
Diarrhea: 4 people, 6.15%
Thyroid Cancer: 4 people, 6.15%
Hypophosphataemia (electrolyte disturbance in which there is an abnormally low level of phosphate in the blood): 4 people, 6.15%
Nausea And Vomiting: 4 people, 6.15%

* Approximation only. Some reports may have incomplete information.

Do you take Cabozantinib and have Weakness?

- Check whether Weakness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cabozantinib:

Cabozantinib (1,313 reports)

Weakness treatments and more:

Weakness (586,877 reports)

Browse all side effects of Cabozantinib:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weakness:

Weakness (3,638 drugs)

Browse all the conditions that are associated with Weakness:

Weakness (6,618 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on cabozantinib (the active ingredients of Cabozantinib) and Cabozantinib (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.